MeiraGTx CFO & COO Richard Giroux sells $557,200 in company shares

Richard Giroux, Chief Financial Officer and Chief Operating Officer of MeiraGTx Holdings plc (NASDAQ:MGTX), sold 56,000 ordinary shares of the company’s stock on October 20, 2026, for a total value of $557,200.

The shares were sold at a weighted average price of $9.95, with individual transactions occurring within a price range of $9.5188 to $10.12. The sale was executed pursuant to a Rule 10b5-1 trading plan, which Mr. Giroux adopted on November 18, 2025.

Following this transaction, Mr. Giroux directly holds 852,530 ordinary shares. Additionally, 5,152 shares are held indirectly by his spouse, and 85,000 shares are held indirectly by Aigle Healthcare Partners III LLC.The insider sale comes as MGTX stock trades at $9.97, near the transaction price, with shares up 25% year-to-date despite recent weakness. According to InvestingPro analysis, the stock appears undervalued at current levels. InvestingPro Tips highlight that the company has been profitable over the last twelve months and liquid assets exceed short-term obligations. Investors can access 8 additional ProTips and comprehensive financial metrics on the platform.

In other recent news, MeiraGTx Holdings has been the focus of analyst attention with differing perspectives. Goldman Sachs initiated coverage on MeiraGTx with a Neutral rating and set a price target of $16.00. The firm highlighted the company’s clinical-stage work on gene therapies for conditions like inherited retinal diseases and Parkinson’s disease. In contrast, Raymond James maintains a Strong Buy rating on MeiraGTx, expressing optimism following pivotal data from Beacon Therapeutics on a similar gene therapy. MeiraGTx’s lead asset, bota-vec, targets X-linked retinitis pigmentosa, with significant developments expected. The company recently reacquired the rights to bota-vec from Johnson & Johnson after a trial failed to meet its primary endpoint. These developments indicate ongoing interest and activity around MeiraGTx’s therapeutic programs.